US FDA rejects closely watched lung cancer drug from China
详细摘要
US FDA rejects closely watched lung cancer drug ivonescimab from China after trial failed to show a survival benefit. Read more at straitstimes.com.
The US Food and Drug Administration said the global clinical trial had not shown a statistically significant extension in patients’ lives.
The US Food and Drug Administration (FDA) rejected a first-of-its-kind cancer drug that was invented in China, a setback for a medicine that had become a symbol of China’s ascendance as a powerhouse in drug development.
Summit Therapeutics, the Florida company that has been seeking to bring the drug to the US market, disclosed the agency’s decision in a news release on Nov 15. Summit bought the US rights to the drug from Akeso Biopharma, a Chinese drugmaker that invented the drug in its laboratories and sells it in China.
文章开头,摘自The Straits Times。如需阅读全文,请前往媒体网站。
MarketNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (www.straitstimes.com)




